Pharmasset, Inc. Company Profile

10:32 EDT 30th May 2015 | BioPortfolio

We are a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Our primary focus is on the development of oral therapeutics for the treatment of human immunodeficiency virus, or HIV, hepatitis B virus, or HBV, and hepatitis C virus, or HCV. Our research and development efforts focus on a class of compounds known as nucleoside analogs, which act to inhibit the natural enzymes required for viral replication.

Location

303-A College Road East
Princeton
New Jersey
08540
United States of America

Contact

Phone: (609) 613-4100
Fax: (609) 613-4150
Email: info@pharmasset.com


News Articles [8 Associated News Articles listed on BioPortfolio]

Pharmasset, Inc (VRUS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary Pharmasset, Inc. (Pharmasset.) is a health care pharmaceutical company. The company is engaged in discovering, producing and commercializing medicines to treat viral infections. The company fo...

Cocrystal Pharma - Overhyped Biotech Or The Next Pharmasset?

Tekmira Merges to Create HBV Powerhouse as ex-Pharmasset Geniuses Seek an Encore

New Trial Data, PTV News: May 05, 2010

Pharmasset announce promising results for experimental Hepatitis C therapy

Pharmasset, Inc (VRUS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Recently added to the BioPortfolio report store, Pharmasset, Inc (VRUS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile is a new report from GlobalData published on 2014-11-16. This ...

Costs of New Treatments for Hepatitis C Infection—Reply

In Reply Dr Lopert and Mr Welch and Dr Green make the point that the Gilead purchase of Pharmasset does not accurately reflect the true costs of development of sofosbuvir. We agree.

News Headlines, PTV News: May 05, 2010

A look at today's forthcoming news stories: Sales up but profits down for Pfizer and Merck & Co after mega-mergers; disappointment for Dainippon as epilepsy drug fails to win approval, and US drug dev...

HBV play OnCore to merge with Tekmira

Tekmira Pharmaceuticals Corp. (TSX:TKM; NASDAQ:TKMR) surged $8.98 (57%) to $24.68 on Monday after announcing plans to merge with OnCore Biopharma Inc. (Doylestown, Pa.). Under the proposed merger, OnC...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [1 Associated Companies listed on BioPortfolio]

Pharmasset, Inc.

We are a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Our primary focus is on the development of oral therapeut...

More Information about "Pharmasset, Inc." on BioPortfolio

We have published hundreds of Pharmasset, Inc. news stories on BioPortfolio along with dozens of Pharmasset, Inc. Clinical Trials and PubMed Articles about Pharmasset, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Pharmasset, Inc. Companies in our database. You can also find out about relevant Pharmasset, Inc. Drugs and Medications on this site too.

Search BioPortfolio:
Loading
Advertisement

Relevant Topic

Human Immuno Deficiency Virus (HIV)
Latest News Clinical Trials Research Drugs Reports Corporate
Human Immunodeficiency Virus (HIV), the causative agent of AIDS. The Human Immunodeficiency Virus, more commonly known as HIV, is a member of the lentivirus sub-set of the retrovirus family of pathogens. It causes AIDS, or Acquired Immuno Deficiency Sy...

Advertisement

Corporate Database Quicklinks



Searches Linking to this Company Record